-+ 0.00%
-+ 0.00%
-+ 0.00%
French Drugmaker Sanofi Wins EU Nod for Rabies Vaccine VaxRabeo
Share
Listen to the news
01:32 AM EST, 11/19/2026 (MT Newswires) -- Sanofi (SAN.PA) secured the European Commission's marketing authorization for its rabies vaccine VaxRabeo, marking its first approval. The vaccine is approved for pre-exposure prophylaxis and post-exposure prophylaxis against rabies across all age groups, the French drugmaker said Thursday. Sanofi added that VaxRabeo has a longer shelf life than its current rabies vaccines. The approval follows a positive opinion from the European Medicines Agency's human medicines committee in September. It is backed by a comprehensive clinical program comparing VaxRabeo with Sanofi's existing rabies vaccines in both pre- and post-exposure settings, covering all age groups and World Health Organization-recommended vaccination schedules.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending